The role of sodium – glucose cotransporter-2 inhibitors in the treatment of different phenotypes of chronic heart failure

Authors

DOI:

https://doi.org/10.14739/mmt.2024.1.296545

Keywords:

sodium-glucose cotransporter-2 inhibitors, congestive heart failure, inhibitors

Abstract

The number of patients with chronic heart failure syndrome is steadily increasing worldwide and Ukraine is not an exception. About 50 % of patients with heart failure have preserved ejection fraction of left ventricle. Recently, there has been significant progress in the diagnosis of this phenotype of heart failure, many diagnostic scales and practice-oriented algorithms have been developed, but the issue of treatment of chronic heart failure remains open.

Aim of the study. To summarize and analyze the results of large-scale randomized trials and to discuss the possible pathophysiological mechanisms underlying the “pleiotropiс” effects of sodium-glucose cotransporter-2 inhibitors.

Sodium-glucose cotransporter-2 inhibitors are the first class of antidiabetic drugs that have demonstrated improved cardiovascular prognosis in patients with chronic heart failure with preserved ejection fraction regardless of the presence of diabetes mellitus.

Conclusions. The necessity of prescribing sodium-glucose cotransporter-2 inhibitors in a cohort of patients with heart failure, regardless of left ventricular ejection fraction, has the highest level of evidence. The pathophysiological mechanisms underlying these effects are not fully understood. Further trials will allow us to identify new mechanisms of action and establish potential relationships between them.

Author Biographies

M. Yu. Kolesnyk, Zaporizhzhia State Medical and Pharmaceutical University, Ukraine

MD, PhD DSc, Professor of the Department of Therapy and Cardiology

Ya. Yu. Maistrovych, Zaporizhzhia State Medical and Pharmaceutical University, Ukraine

MD, PhD student of the Department of Therapy and Cardiology

References

  1. Sun Y, Wang N, Li X, Zhang Y, Yang J, Tse G, et al. Predictive value of H2FPEF score in patients with heart failure with preserved ejection fraction. ESC Heart Failure. 2021;8(2):1244-52. doi: https://doi.org/10.1002/ehf2.13187
  2. Kolesnyk MY, Maistrovych YY. [Current diagnostic algorithms for chronic heart failure with preserved left ventricular ejection fraction]. Zaporozhye medical journal. 2023;25(1):72-80. Ukrainian. doi: https://doi.org/10.14739/2310-1210.2023.1.270044
  3. Rosano GM, Moura B, Metra M, Böhm M, Bauersachs J, Ben Gal T, et al. Patient profiling in heart failure for tailoring medical therapy. A consensus document of the heart failure association of the European Society of Cardiology. Eur J Heart Fail. 2021;23(6):872-81. doi: https://doi.org/10.1002/ejhf.2206
  4. Kjeldsen SE, von Lueder TG, Smiseth OA, Wachtell K, Mistry N, Westheim AS, et al. Medical therapies for heart failure with preserved ejection fraction. Hypertension. 2020;75(1):23-32. doi: https://doi.org/10.1161/hypertensionaha.119.14057
  5. Kuno T, Ueyama H, Fujisaki T, Briasouli A, Takagi H, Briasoulis A. Meta-analysis evaluating the effects of renin-angiotensin-aldosterone system blockade on outcomes of heart failure with preserved ejection fraction. Am J Cardiol. 2020;125(8):1187-93. doi: https://doi.org/10.1016/j.amjcard.2020.01.009
  6. Solomon SD, McMurray JJ, Anand IS, Ge J, Lam CS, Maggioni AP, et al. Angiotensin–NEPRILYSIN inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381(17):1609-20. doi: https://doi.org/10.1056/nejmoa1908655
  7. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-726. doi: https://doi.org/10.1093/eurheartj/ehab368
  8. Fonseca-Correa JI, Correa-Rotter R. Sodium-glucose cotransporter 2 inhibitors mechanisms of action: A Review. Front Med (Lausanne). 2021;8:777861. doi: https://doi.org/10.3389/fmed.2021.777861
  9. Tentolouris A, Vlachakis P, Tzeravini E, Eleftheriadou I, Tentolouris N. SGLT2 inhibitors: A review of their antidiabetic and cardioprotective effects. Int J Environ Res Public Health. 2019;16(16):2965. doi: https://doi.org/10.3390/ijerph16162965
  10. Gallo LA, Wright EM, Vallon V. Probing SGLT2 as a therapeutic target for diabetes: Basic physiology and consequences. Diab Vasc Dis Res. 2015;12(2):78-89. doi: https://doi.org/10.1177/1479164114561992
  11. Rosas-Guzman J, Rosas-Saucedo J, Romero-Garcia A. SGLT2 inhibitors in diabetes mellitus treatment. Rev Recent Clin Trials. 2017;12(1):8-18. doi: https://doi.org/10.2174/1574887111666160829145810
  12. Liki Control [Internet]. JARDIANCE® UA/14980/01/01 [updated 2023 Dec 3; cited 2024 Jan 2]. Available from: https://likicontrol.com.ua/%D1%96%D0%BD%D1%81%D1%82%D1%80%D1%83%D0%BA%D1%86%D1%96%D1%8F/?%5B35733%5D
  13. Liki Control [Internet]. FORXIGA® UA/13302/01/01 [updated 2024 Jan 3; cited 2024 Jan 2]. Available from: https://likicontrol.com.ua/%D1%96%D0%BD%D1%81%D1%82%D1%80%D1%83%D0%BA%D1%86%D1%96%D1%8F/?%5B28467%5D
  14. Cinti F, Moffa S, Impronta F, Cefalo CM, Sun VA, Sorice GP, et al. Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date. Drug Des Devel Ther. 2017;11:2905-19. doi: https://doi.org/10.2147/DDDT.S114932
  15. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-28. doi: https://doi.org/10.1056/nejmoa1504720
  16. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644-57. doi: https://doi.org/10.1056/nejmoa1611925
  17. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(19):1880-2. doi: https://doi.org/10.1056/nejmc1902837
  18. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. New N Engl J Med. 2019;381(21):1995-2008. doi: https://doi.org/10.1056/nejmoa1911303
  19. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with Empagliflozin in heart failure. New N Engl J Med. 2020;383(15):1413-24. doi: https://doi.org/10.1056/nejmoa2022190
  20. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. New N Engl J Med. 2021;385(16):1451-61. doi: https://doi.org/10.1056/nejmoa2107038
  21. Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. New N Engl J Med. 2022;387(12):1089-98. doi: https://doi.org/10.1056/nejmoa2206286
  22. Lam CSP, Chandramouli C, Ahooja V, Verma S. SGLT-2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects. J Am Heart Assoc. 2019;8(20):e013389. doi: https://doi.org/10.1161/JAHA.119.013389
  23. Hallow KM, Helmlinger G, Greasley PJ, McMurray JJ, Boulton DW. Why do sglt2 inhibitors reduce heart failure hospitalization? a differential volume regulation hypothesis. Diabetes Obes Metab. 2017;20(3):479-87. doi: https://doi.org/10.1111/dom.13126
  24. Ferrannini E, Mark M, Mayoux E. CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis. Diabetes Care. 2016;39(7):1108-14. doi: https://doi.org/10.2337/dc16-0330
  25. Packer M, Anker SD, Butler J, Filippatos G, Zannad F. Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure. JAMA Cardiol. 2017;2(9):1025. doi: https://doi.org/10.1001/jamacardio.2017.2275
  26. Patoulias D, Fragakis N, Rizzo M. The therapeutic role of SGLT-2 inhibitors in acute heart failure: From pathophysiologic mechanisms to clinical evidence with pooled analysis of relevant studies across safety and efficacy endpoints of interest. Life. 2022;12(12):2062. doi: https://doi.org/10.3390/life12122062
  27. Brust-Sisti L, Rudawsky N, Gonzalez J, Brunetti L. The role of sodium-glucose cotransporter-2 inhibition in heart failure with preserved ejection fraction. Pharmacy. 2022;10(6):166. doi: https://doi.org/10.3390/pharmacy10060166
  28. Verma S, McMurray JJ. SGLT2 inhibitors and mechanisms of cardiovascular benefit: A state-of-the-art review. Diabetologia. 2018;61(10):2108-17. doi: https://doi.org/10.1007/s00125-018-4670-7
  29. Sitina M, Lukes M, Sramek V. Empagliflozin-associated postoperative mixed metabolic acidosis. case report and review of pathogenesis. BMC Endocr Disord. 2023;23(1). doi: https://doi.org/10.1186/s12902-023-01339-w
  30. Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors. JACC Basic Transl Sci. 2020;5(6):632-44. doi: https://doi.org/10.1016/j.jacbts.2020.02.004
  31. Vallon V, Thomson SC. Targeting renal glucose reabsorption to treat hyperglycaemia: The pleiotropic effects of SGLT2 inhibition. Diabetologia. 2016;60(2):215-25. doi: https://doi.org/10.1007/s00125-016-4157-3
  32. Natali A, Nesti L, Tricò D, Ferrannini E. Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: A narrative review of clinical evidence. Cardiovasc Diabetol. 2021;20(1):196. doi: https://doi.org/10.1186/s12933-021-01385-5
  33. Ceriello A, Genovese S, Mannucci E, Gronda E. Glucagon and heart in type 2 diabetes: New perspectives. Cardiovasc Diabetol. 2016;15(1):123. doi: https://doi.org/10.1186/s12933-016-0440-3
  34. Ferrannini E, Baldi S, Frascerra S, Astiarraga B, Barsotti E, Clerico A, et al. Renal handling of ketones in response to sodium–glucose cotransporter 2 inhibition in patients with type 2 diabetes. Diabetes Care. 2017;40(6):771-6. doi: https://doi.org/10.2337/dc16-2724
  35. Griffin M, Rao VS, Ivey-Miranda J, Fleming J, Mahoney D, Maulion C, et al. Empagliflozin in heart failure. Circulation. 2020;142(11):1028-39. doi: https://doi.org/10.1161/circulationaha.120.045691
  36. Dick SA, Epelman S. Chronic heart failure and inflammation. Circ Res. 2016;119(1):159-76. doi: https://doi.org/10.1161/circresaha.116.308030
  37. Mehta JL, Pothineni NV. Inflammation in heart failure. Hypertension. 2016;68(1):27-9. doi: https://doi.org/10.1161/hypertensionaha.116.07307
  38. Iannantuoni F, M. de Marañon A, Diaz-Morales N, Falcon R, Bañuls C, Abad-Jimenez Z, et al. The SGLT2 inhibitor Empagliflozin ameliorates the inflammatory profile in type 2 diabetic patients and promotes an antioxidant response in leukocytes. Journal of Clinical Medicine. 2019;8(11):1814. doi: https://doi.org/10.3390/jcm8111814
  39. Heerspink HJ, Perco P, Mulder S, Leierer J, Hansen MK, Heinzel A, et al. Canagliflozin reduces inflammation and fibrosis biomarkers: A potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease. Diabetologia. 2019;62(7):1154-66. doi: https://doi.org/10.1007/s00125-019-4859-4
  40. Leng W, Wu M, Pan H, Lei X, Chen L, Wu Q, et al. The SGLT2 inhibitor Dapagliflozin attenuates the activity of ROS-NLRP3 inflammasome axis in steatohepatitis with diabetes mellitus. Ann Transl Med. 2019;7(18):429. doi: https://doi.org/10.21037/atm.2019.09.03
  41. Lee TM, Chang NC, Lin SZ. Dapagliflozin, a selective SGLT2 inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic Biol Med. 2017;104:298-310. doi: https://doi.org/10.1016/j.freeradbiomed.2017.01.035
  42. Kang S, Verma S, Hassanabad AF, Teng G, Belke DD, Dundas JA, et al. Direct effects of Empagliflozin on extracellular matrix remodelling in human cardiac myofibroblasts: Novel translational clues to explain Empa-Reg Outcome results. Can J Cardiol. 2020;36(4):543-53. doi: https://doi.org/10.1016/j.cjca.2019.08.033
  43. Grubić Rotkvić P, Cigrovski Berković M, Bulj N, Rotkvić L. Minireview: Are SGLT2 inhibitors heart savers in diabetes? Heart Fail Rev. 2019;25(6):899-905. doi: https://doi.org/10.1007/s10741-019-09849-3
  44. Lee Y, Kim SR, Han DH, Yu HT, Han YD, Kim JH, et al. Senescent T cells predict the development of hyperglycemia in humans. Diabetes. 2018;68(1):156-62. doi: https://doi.org/10.2337/db17-1218
  45. Ye Y, Jia X, Bajaj M, Birnbaum Y. Dapagliflozin attenuates na+/h+ exchanger-1 in cardiofibroblasts via AMPK activation. Cardiovasc Drugs Ther. 2018;32(6):553-8. doi: https://doi.org/10.1007/s10557-018-6837-3
  46. Byrne NJ, Matsumura N, Maayah ZH, Ferdaoussi M, Takahara S, Darwesh AM, et al. Empagliflozin blunts worsening cardiac dysfunction associated with reduced NLRP3 (nucleotide-binding domain-like receptor protein 3) inflammasome activation in heart failure. Circ Heart Fail. 2020;13(1):e006277. doi: https://doi.org/10.1161/circheartfailure.119.006277
  47. Kravchun PH, Ryndina NH. Syndrom kardiorenalnoi anemii [Cardiorenal anemia syndrome]. Kharkiv, Ukraine: FOP Mezina V.V.; 2018.
  48. Kanbay M, Tapoi L, Ureche C, Tanriover C, Cevik E, Demiray A, et al. Effect of sodium–glucose cotransporter 2 inhibitors on hemoglobin and hematocrit levels in type 2 diabetes: A systematic review and meta-analysis. Int Urol Nephrol. 2021;54(4):827-41. doi: https://doi.org/10.1007/s11255-021-02943-2
  49. Ghanim H, Abuaysheh S, Hejna J, Green K, Batra M, Makdissi A, et al. Dapagliflozin suppresses hepcidin and increases erythropoiesis. J Clin Endocrinol Metab. 2020;105(4):dgaa057. doi: https://doi.org/10.1210/clinem/dgaa057
  50. Soga F, Tanaka H, Tatsumi K, Mochizuki Y, Sano H, Toki H, et al. Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure. Cardiovasc Diabetol. 2018;17(1). doi: 10.1186/s12933-018-0775-z
  51. Shi FH, Li H, Shen L, Xu L, Ge H, Gu ZC, et al. Beneficial effect of sodium-glucose co-transporter 2 inhibitors on left ventricular function. J Clin Endocrinol Metab. 2021;107(4):1191-203. doi: https://doi.org/10.1210/clinem/dgab834
  52. Theofilis P, Antonopoulos AS, Katsimichas T, Oikonomou E, Siasos G, Aggeli C, et al. The impact of SGLT2 inhibition on imaging markers of cardiac function: A systematic review and meta-analysis. Pharmacol Res. 2022;180:106243. doi: https://doi.org/10.1016/j.phrs.2022.106243
  53. Lim VG, Bell RM, Arjun S, Kolatsi-Joannou M, Long DA, Yellon DM. SGLT2 inhibitor, Canagliflozin, attenuates myocardial infarction in the diabetic and Nondiabetic heart. JACC Basic Transl Sci. 2019;4(1):15-26. doi: https://doi.org/10.1016/j.jacbts.2018.10.002
  54. Mustroph J, Wagemann O, Lücht CM, Trum M, Hammer KP, Sag CM, et al. Empagliflozin reduces ca/calmodulin-dependent kinase ii activity in isolated ventricular cardiomyocytes. ESC Heart Fail. 2018;5(4):642-8. doi: https://doi.org/10.1002/ehf2.12336
  55. Dalama B, Mesa J. New oral hypoglycemic agents and cardiovascular risk. crossing the metabolic border. Rev Esp Cardiol (Engl Ed). 2016;69(11):1088-97. doi: https://doi.org/10.1016/j.rec.2016.07.008
  56. Epstein B, Rosenwasser R, Sutton D, Choksi R, Sultan. SGLT-2 inhibitors and their potential in the treatment of diabetes. Diabetes Metab Syndr Obes. 2013;453. doi: https://doi.org/10.2147/dmso.s34416
  57. Bailey CJ. Uric acid and the cardio-renal effects of SGLT2 inhibitors. Diabetes Obes Metab. 2019;21(6):1291-8. doi: https://doi.org/10.1111/dom.13670
  58. Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou F-F, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436-46. doi: https://doi.org/10.1056/nejmoa2024816
  59. Cherney D, Lund SS, Perkins BA, Groop P-H, Cooper ME, Kaspers S, et al. The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes. Diabetologia. 2016;59(9):1860-70. doi: https://doi.org/10.1007/s00125-016-4008-2

Downloads

Published

2024-03-22

How to Cite

Kolesnyk, M. Y., & Maistrovych, Y. Y. (2024). The role of sodium – glucose cotransporter-2 inhibitors in the treatment of different phenotypes of chronic heart failure. Modern Medical Technology, 16(1), 60–67. https://doi.org/10.14739/mmt.2024.1.296545

Issue

Vol. 16 No. 1 (2024)

Section

Reviews of literature

License

The work is provided under the terms of the Public Offer and of Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). This license allows an unlimited number of persons to reproduce and share the Licensed Material in all media and formats. Any use of the Licensed Material shall contain an identification of its Creator(s) and must be for non-commercial purposes only.